HLA-DR Monoclonal Antibody (YD1/63.4.10), PE, Invitrogen™

Description

• MA5-18022 targets HLA-DR in FACS applications and shows reactivity with Human samples
• The MA5-18022 immunogen is dAUDI cells
• HLA-DR, like other MHC class II molecules, is a transmembrane glycoprotein composed of a 36 kDa alpha chain (DRA) and 27 kDa beta chain (DRB)
• The alpha chain gene contains 5 exons
• Exon 1 encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, and exon 4 encodes the transmembrane domain and the cytoplasmic tail
• DRA does not have polymorphisms in the peptide binding part and acts as the sole alpha chain for DRB1, DRB3, DRB4 and DRB5
• Within the DR molecule the beta chain contains all the polymorphisms specifying the peptide binding specificities
• Hundreds of DRB1 alleles have been described and typing for these polymorphisms is routinely done for bone marrow and kidney transplantation
• HLA-DR is expressed primarily on antigen presenting cells such as B lymphocytes, monocytes, macrophages, thymic epithelial cells and activated T lymphocytes
• Three loci, DR, DQ and DP, encode the major expressed products of the human class II region
• The human MHC class II molecules bind intracellularly processed peptides, present them to T-helper cells, and have a critical role in the initiation of the immune response
• HLA and MHC antibodies play a significant role in Immunopeptidomics, facilitating the identification and characterization of neoantigens through high-performance liquid chromatography coupled to tandem Mass Spectrometry.